Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 17;24(4):4044.
doi: 10.3390/ijms24044044.

New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination

Marta Pina Fernandes  1 , Cristina Oliveira  1 , Hugo Sousa  2   3   4   5   6   7 , Júlio Oliveira  1   2   8
Affiliations
Review

New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination

Marta Pina Fernandes et al. Int J Mol Sci. .

Abstract

Lung cancer is the second most common cancer in the world, being the first cause of cancer-related mortality. Surgery remains the only potentially curative treatment for Non-Small Cell Lung Cancer (NSCLC), but the recurrence risk remains high (30-55%) and Overall Survival (OS) is still lower than desirable (63% at 5 years), even with adjuvant treatment. Neoadjuvant treatment can be helpful and new therapies and pharmacologic associations are being studied. Immune Checkpoint Inhibitors (ICI) and PARP inhibitors (PARPi) are two pharmacological classes already in use to treat several cancers. Some pre-clinical studies have shown that its association can be synergic and this is being studied in different settings. Here, we review the PARPi and ICI strategies in cancer management and the information will be used to develop a clinical trial to evaluate the potential of PARPi association with ICI in early-stage neoadjuvant setting NSCLC.

Keywords: EARLY-stage NSCLC; PARP inhibitors; combination therapy; immunotherapy; neoadjuvant setting; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Anti-CTLA-4 mechanism of action (image adapted from [37,38]).
Figure 2
Figure 2
Anti-PD-1/PD-L1 mechanism of action (image adapted from [37]).
Figure 3
Figure 3
PARP inhibitors mechanism of action (image adapted from [75]).
Figure 4
Figure 4
PARP inhibitor and immunotherapy combination mechanism of action (image adapted from [37,38,75]).
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Rolf A., Stahel S.P. In: Thoracic Tumours: Essentials for Clinicians. 2nd ed. Marina Chiara Garassino, editor. ESMO Press; Lugano, Switzerland: 2019.
    1. Hoffman P.C., Mauer A.M., Vokes E.E. Lung cancer. Lancet. 2000;355:479–485. doi: 10.1016/S0140-6736(00)82038-3. - DOI - PubMed
    1. Szeto C.H., Shalata W., Yakobson A., Agbarya A. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future. J. Clin. Med. 2021;10:5614. doi: 10.3390/jcm10235614. - DOI - PMC - PubMed
    1. Alexander M., Kim S.Y., Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer. Lung. 2020;198:897–907. doi: 10.1007/s00408-020-00407-5. - DOI - PMC - PubMed

MeSH terms

Substances